Andrea Lobo,  —

LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow the company to market the device as a Class IIb medical device. NO causes blood vessels to relax and widen, lowering…

Body weight-adjusted Uptravi (selexipag) dosing for children and adolescents with pulmonary arterial hypertension (PAH) resulted in exposure to the treatment’s active ingredient comparable to that in adults with PAH, a study showed. The study assessed the treatment’s pharmacokinetics — its…

The U.S. Food and Drug Administration (FDA) has provided Tiakis Biotech with advice for a planned Phase 2 clinical trial testing tiprelestat for pulmonary arterial hypertension (PAH). The ATHENA trial, which will assess the treatment’s safety and efficacy, is expected to enroll 90 patients, randomly assigned to receive…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen’s experimental treatment for pulmonary arterial hypertension (PAH). That designation aims to support the development of therapies for rare diseases, or those affecting fewer than 200,000 people in the U.S. It comes with certain…

Blood levels of angiopoietin-2, a marker of blood vessel damage, may help predict treatment response and outcomes in pulmonary arterial hypertension (PAH), according to a new study from researchers in the U.S. Levels of D-dimer, a marker of blood clot formation, were also increased in PAH patients, the study…

Indicators of high blood sugar levels, particularly stress hyperglycemia ratio (SHR), may predict clinical worsening in people with idiopathic pulmonary arterial hypertension, a study in China indicates. Clinical worsening was defined as the first occurrence of lung transplant, being rehospitalized due to heart failure, or death from any cause.

A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…

Abnormalities in blood levels of various microRNAs (miRNAs) — small RNA molecules that regulate other genes in protein production — may contribute to the development and progression of chronic thromboembolic pulmonary…

A new device to deliver inhaled nitric oxide gas to newborns with pulmonary hypertension (PH), is now available for use in hospital neonatal intensive care units (NICUs) across the U.S. The rollout follows recent approval from the U.S. Food and Drug Administration of the next-generation device, the INOmax…

Exosomes, a type of small vesicle released by mesenchymal stem cells (MSCs), helped reduce vascular remodeling and ease pulmonary hypertension (PH) symptoms in a rat model of the disease, a study found. Exosome effects were tied to a modulation of the NF-kB/BMP pathway involved in vascular remodeling, a set…

Liquidia has expanded a license agreement with Pharmosa Biopharm, acquiring rights to market L606, a potential inhaled formulation of treprostinil now in a Phase 3 study, across Europe, Japan, and other regions as well as in North America. The two-part and open-label Phase 3 clinical…

The use of selenium supplements — an essential mineral naturally present in many foods and added to others — reduced blood vessel remodeling, a hallmark of pulmonary arterial hypertension (PAH), in the lung, according to a new study. Selinium has antioxidant properties and may help protect cells from damage.